429 related items for PubMed ID: 15354206
1. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Buyukberber S, Arslan O, Gurman G, Akan H, Ilhan O.
Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
[Abstract] [Full Text] [Related]
2. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O, Gooley T, Holmberg L, Lilleby K, Clift R, Zuckerman N, Klarnet J, Weaver C, Chauncey T, Bensinger WI.
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[Abstract] [Full Text] [Related]
3. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
Demirer T, Ilhan O, Mandel NM, Arat M, Günel N, Celebi H, Ustün C, Akan H, Demirer S, Aydintuğ S, Uysal A, Koç H.
Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
[Abstract] [Full Text] [Related]
4. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
Demirer T, Uysal VA, Ayli M, Genc Y, Ilhan O, Koc H, Dagli M, Arat M, Gunel N, Fen T, Dincer S, Ustael N, Yildiz M, Ustun T, Seyrek E, Ozet G, Muftuoglu O, Akan H.
Bone Marrow Transplant; 2003 May; 31(9):755-61. PubMed ID: 12732881
[Abstract] [Full Text] [Related]
5. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[Abstract] [Full Text] [Related]
6.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
7.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
8. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP, Roitman D, Miller KB, Morelli J, Stadtmauer E, Pecora AL, Cassileth P, Fernandez H, Cooper BW, Kutteh L, Lazarus HM.
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[Abstract] [Full Text] [Related]
9. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[Abstract] [Full Text] [Related]
10. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L, Vidriales B, del Cañizo MC, Corral M, Gonzalez M, León A, Jean-Paul E, Rocha E, Moraleda JM, San Miguel JF.
Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
[Abstract] [Full Text] [Related]
11. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
Schiffman KS, Bensinger WI, Appelbaum FR, Rowley S, Lilleby K, Clift RA, Weaver CH, Demirer T, Sanders JE, Petersdorf S, Gooley T, Weiden P, Zuckerman N, Montgomery P, Maziarz R, Klarnet JP, Rivkin S, Trueblood K, Storb R, Holmberg L, Buckner CD.
Bone Marrow Transplant; 1996 Jun; 17(6):943-50. PubMed ID: 8807098
[Abstract] [Full Text] [Related]
12. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.
Holmberg LA, Demirer T, Rowley S, Buckner CD, Goodman G, Maziarz R, Klarnet J, Zuckerman N, Harrer G, McCloskey R, Gersh R, Goldberg R, Nichols W, Jacobs A, Weiden P, Montgomery P, Rivkin S, Appelbaum FR, Bensinger WI.
Bone Marrow Transplant; 1998 Oct; 22(7):651-9. PubMed ID: 9818692
[Abstract] [Full Text] [Related]
13. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[Abstract] [Full Text] [Related]
14. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[Abstract] [Full Text] [Related]
15. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
Lee SM, Ryder WD, Clemons MJ, Morgenstern GR, Chang J, Scarffe JH, Radford JA.
Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
[Abstract] [Full Text] [Related]
16. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
Glossmann JP, Staak JO, Nogova L, Diehl V, Scheid C, Kisro J, Reis HE, Peter N, Engert A, Josting A.
Ann Hematol; 2005 Aug; 84(8):517-25. PubMed ID: 15759115
[Abstract] [Full Text] [Related]
17. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD, Hoppe RT, Amylon MD, Brown BW, Wong RM, Blume KG.
Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
[Abstract] [Full Text] [Related]
18. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, Gabriele A, Bonifazi F, Salvucci M, Tura S, Baccarani M.
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[Abstract] [Full Text] [Related]
19. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI, Roitman D, Tsang R, Stewart AK, Keating A, Crump M.
Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
[Abstract] [Full Text] [Related]
20. High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: results of outpatient treatment in community cancer centers.
Weaver CH, Schwartzberg L, Zhen B, Mangum M, Leff R, Tauer K, Rosenberg A, Pendergrass K, Kaywin P, Hainsworth J, Greco FA, West WH, Buckner CD.
Bone Marrow Transplant; 1997 Nov; 20(9):753-60. PubMed ID: 9384477
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
